Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2

[1]  J. Boudreau,et al.  KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Toby C. Cornish,et al.  Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma , 2016, Gut.

[3]  R. Figlin,et al.  The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma , 2014, Clinical Cancer Research.

[4]  M. Czuczman,et al.  CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells , 2014, Cancer Immunology Research.

[5]  J. Klein,et al.  Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia , 2014, The Journal of Immunology.

[6]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[7]  E. Plimack,et al.  PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection , 2013, Cancer Immunology Research.

[8]  K. Hsu,et al.  Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. , 2012, The Journal of clinical investigation.

[9]  J. Chewning,et al.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. , 2012, The New England journal of medicine.

[10]  D. Davis,et al.  Human NK Cells Differ More in Their KIR2DL1-Dependent Thresholds for HLA-Cw6-Mediated Inhibition than in Their Maximal Killing Capacity , 2011, PloS one.

[11]  M. Pillon,et al.  KIR/HLA‐I mismatching and risk of relapse in paediatric patients undergoing non‐haploidentical allogeneic haematopoietic stem cell transplantation , 2011, Pediatric transplantation.

[12]  Andrew R. Jones,et al.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..

[13]  J. Maris,et al.  Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. , 2010, Cancer research.

[14]  Chap T Le,et al.  Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. , 2010, Blood.

[15]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[16]  A. Cambon-Thomsen,et al.  Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analyses , 2010, Immunogenetics.

[17]  W. Hwang,et al.  Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients , 2010, Bone Marrow Transplantation.

[18]  K. Hsu,et al.  KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma , 2009, Clinical Cancer Research.

[19]  J. Vicario,et al.  KIR–HLA receptor‐ligand mismatch associated with a graft‐versus‐tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors , 2009, Pediatric blood & cancer.

[20]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[21]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[22]  Peter Parham,et al.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. , 2009, Blood.

[23]  P. Parham,et al.  Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL31 , 2008, The Journal of Immunology.

[24]  J. Piccirillo,et al.  HLA alleles determine differences in human natural killer cell responsiveness and potency , 2008, Proceedings of the National Academy of Sciences.

[25]  C. Vilches,et al.  Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. , 2007, Tissue antigens.

[26]  R. Handgretinger,et al.  Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma , 2007, British Journal of Cancer.

[27]  J. Chewning,et al.  KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro1 , 2007, The Journal of Immunology.

[28]  S. Gasser,et al.  Activation and self‐tolerance of natural killer cells , 2006, Immunological reviews.

[29]  M. Carrington,et al.  The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. , 2006, Annual review of genomics and human genetics.

[30]  E. Seifried,et al.  Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands. , 2003, Human immunology.

[31]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[32]  P. Parham,et al.  NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules , 1994, The Journal of experimental medicine.

[33]  R. Seeger,et al.  Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin‐2 Induces Antibody‐Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[34]  J. Monson,et al.  Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[35]  R. R. Robinson,et al.  Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. , 1990, Cancer research.

[36]  W. Greene,et al.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. , 1988, The Journal of clinical investigation.

[37]  J. Thompson,et al.  Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. , 1987, Cancer research.

[38]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.